Why the study?
Does spironolactone prevent angiographic in-stent restenosis in patients with significant coronary artery disease undergoing coronary stenting?
Does spironolactone prevent angiographic in-stent restenosis in patients with significant coronary artery disease undergoing coronary stenting?
Spironolactone 50 mg twice daily for 6 months does not significantly reduce the rate of angiographic in-stent restenosis after coronary stenting compared to placebo.
No takes yet. Share an insight, caveat, or question.
Spironolactone adds no value for in-stent restenosis prevention; this RCT closes the hypothesis for mineralocorticoid receptor antagonism post-stenting.
Kurşaklıoğlu et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: